Table 3: Survival estimates by the Kaplan-Meier method. |
|||||
Variable |
Mean ± SD, months |
95% CI |
Survival at one year (%) |
Five-year survival (%) |
p |
Body mass index < 22.06 > 22.06 |
16.00 ± 10.53 47.43 ± 12.2 |
0-36.65 23.51-71.35 |
34.17 64.70 |
NR 48.55 |
0.2 |
Type 2 diabetes mellitus No Yes |
44.50 ± 15.66 23.31 ± 5.7 |
13.79-75.2 12.13-34.49 |
66.45 53.33 |
44.40 NR |
0.73
|
Arterial hypertension No Yes |
41.94 ± 13.7 14.31 ± 3.22 |
15.08-68.80 8-20.63 |
83.30 56.14 |
27.78 NR |
0.28 |
Viral hepatitis No Yes |
37.93 ± 13.00 26.16 ± 7.69 |
12.43-63.42 11.08-41.24 |
66.66 66.67 |
35.56 NR |
0.91 |
Liver cirrhosis No Yes |
15.66 ± 4.04 33.83 ± 10.07 |
7.74-23.59 14.09-53.57 |
67.50 66.10 |
33.75 NR |
0.82 |
Lesion size < 5 cm > 5 cm |
21.75 ± 6.08 51.42 ± 14.03 |
9.83-33.66 23.92-78.92 |
53.57 71.43 |
NR 53.57 |
0.25 |
OKUDA I II |
40.42 ± 11.82 14.16 ± 4.05 |
17.25-63.59 6.21-22.12 |
72.92 50.00 |
27.34 NR |
0.43 |
Alpha fetoprotein < 200 > 200 |
34.37 ± 11.2 14.25 ± 4.95 |
12.40-56.34 4.53-23.96 |
60.61 50.00 |
22.73 NR |
0.68 |
Sorafenib No Yes |
20.00 ± 3.68 38.04 ± 12.45 |
12.78-27.21 13.63-62.44 |
66.45 58.74 |
NR 29.37 |
0.93 |
OKUDA I no positive criteria, II one or two positive, SD = standard deviation, NR = not recorded. |